Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. The company is headquartered in San Diego, California and currently employs 105 full-time employees. The company went IPO on 2024-07-19. The firm is focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Its product candidates are derived from donor cells (allogeneic) rather than a patient's own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patient's treatment location. Its lead product candidate, AlloNK, is being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in patients with autoimmune diseases and cancers, such as systemic lupus erythematosus (SLE), lupus nephritis (LN), RA, PV, the ANCA-associated vasculitis subtypes GPA/MPA, and B-NHL. AlloNK is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted mAbs in an ongoing Phase I/Ib trial in SLE with or without LN and a basket investigator-initiated trial (IIT) in multiple autoimmune indications.
Follow-Up Questions
Artiva Biotherapeutics Inc의 CEO는 누구입니까?
Dr. Fred Aslan은 2021부터 회사에 합류한 Artiva Biotherapeutics Inc의 President입니다.
ARTV 주식의 가격 성능은 어떻습니까?
ARTV의 현재 가격은 $5.03이며, 전 거래일에 decreased 0.17% 하였습니다.
Artiva Biotherapeutics Inc의 주요 사업 주제나 업종은 무엇입니까?
Artiva Biotherapeutics Inc은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
Artiva Biotherapeutics Inc의 시가총액은 얼마입니까?
Artiva Biotherapeutics Inc의 현재 시가총액은 $122.9M입니다
Artiva Biotherapeutics Inc는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 7명의 분석가가 Artiva Biotherapeutics Inc에 대한 분석 평가를 실시했으며, 이는 4명의 강력한 매수, 7명의 매수, 1명의 보유, 0명의 매도, 그리고 4명의 강력한 매도를 포함합니다
